Physician profile
Mercedez Freeman
NPI 1477033421
$615.92
in general payments reported to CMS, 2019-2025
12 companies · $70.52 in 2025
The $70.52 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.66 · 2022: $150 · 2023: $69.80 · 2024: $234 · 2025: $70.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $165.40 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $112.27 | 2021-2024 | M-M-R II, Vaxelis, Vaxneuvance |
| Alk-Abello, INC | $77.83 | 2023-2024 | Ragwitek, Grastek, Odactra |
| Cranial Technologies, INC | $72.59 | 2021-2025 | Doc Band |
| Phadia US INC. | $36.18 | 2021-2022 | |
| Viiv Healthcare Company | $25.52 | 2024 | Apretude |
| Global Blood Therapeutics, INC. | $24.71 | 2022 | |
| Lilly USA, LLC | $24.69 | 2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $21.60 | 2023 | Flumist Quadrivalent |
| Kaleo, INC. | $20.40 | 2022 | |
| Sanofi Pasteur INC. | $19.32 | 2024 | |
| Novo Nordisk INC | $15.41 | 2025 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mercedez Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.